We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App





Fujirebio Showcases Range of Novel Testing Solutions

By LabMedica International staff writers
Posted on 14 Nov 2023
Print article
Image: The LUMIPULSE G series of instruments was on display at MEDICA 2023 (Photo courtesy of Fujirebio)
Image: The LUMIPULSE G series of instruments was on display at MEDICA 2023 (Photo courtesy of Fujirebio)

Fujirebio (Tokyo, Japan) is showcasing its LUMIPULSE G series of chemiluminescent enzyme immunoassay (CLEIA) analyzers and kits for fully automated testing at MEDICA 2023. The LUMIPULSE G series includes the LUMIPULSE G1200 fully automated immunoassay instrument which uses a unique mono test cartridge concept. It has a true throughput of 120 tests per hour and provides outstanding flexibility and easy handling in hospitals and clinical laboratories.

Fujirebio is also highlighting the latest member of the LUMIPULSE G series, the LUMIPULSE G600II which is a compact and robust benchtop analyzer with a constant throughput of 60 tests per hour. The system uses a unique mono test cartridge concept (the same cartridge concept as the mid-sized LUMIPULSE G1200 analyzer) and offers outstanding flexibility and easy handling to hospitals and clinical laboratories. The easy-to-use analyzer provides a perfect fit in laboratories aiming for personalized workflow solutions without compromising testing quality. Fujirebio offers a number of kits for fully automated testing on the LUMIPULSE G series of CLEIA analyzers.

This includes Lumipulse G 25-OH Vitamin D is an immunoreaction cartridge for in vitro diagnostic (IVD) use for the quantitative determination of 25-hydroxyvitamin D (25-OH-D) in human serum or plasma to be used in the assessment of Vitamin D sufficiency. Fujirebio is highlighting the Lumipulse G Aldosterone immunoreaction cartridges for the quantitative measurement of aldosterone in human serum, plasma, or urine. Also being showcased at MEDICA 2023 is the Lumipulse G B•R•A•H•M•S PCT immunoreaction cartridges for IVD use with a two-step sandwich immunoassay method on the LUMIPULSE G system for the quantitative determination of procalcitonin (PCT) in human serum and plasma.

Related Links:
Fujirebio 

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette

Print article

Channels

Clinical Chemistry

view channel
Image: The study demonstrated that electric-field molecular fingerprinting can probe cancer (Photo courtesy of ACS Central Science, 2025, 10.1021/acscentsci.4c02164)

New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma

Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more

Molecular Diagnostics

view channel
Image: The study validated the Lumipulse p-tau21 automated and scalable blood test system (Photo courtesy of Fujirebio)

Blood Test for Early Alzheimer's Detection Achieves Over 90% Accuracy

Alzheimer's disease (AD) is a debilitating condition and a leading cause of disability and death worldwide. The availability of reliable diagnostic tools is currently restricted, and diagnosis often relies... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.